Cat. No. 0729
Chemical Name: 5-[2-(Imidazol-4-yl)ethyl]isothiour
Biological ActivityAn extremely potent, high affinity agonist at H3 and H4 receptors (Ki values are 0.3 and 2.7 nM respectively). Induces shape change in eosinophils with an EC50 of 25 nM. Centrally active following systemic administration. Also available as part of the Histamine H3 Receptor Tocriset™.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Ling et al (2004) Histamine H4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule upregulation. Br.J.Pharmacol. 142 161. PMID: 15131002.
Farzin and Attarzadeh (2000) Influence of different histamine receptor agonists and antagonists on apomorphine-induced licking behavior in rats. Eur.J.Pharmacol. 404 169. PMID: 10980276.
Garbarg et al (1992) S-[2-(4-Imidazolyl)ethyl]isothiourea, a highly specific and potent histamine H3 receptor agonist. J.Pharmacol.Exp.Ther. 263 304. PMID: 1383495.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for Imetit dihydrobromide include:
Hashikawa-Hobara et al (2012) Histamine 3 receptor activation reduces the expression of neuronal angiotensin II type 1 receptors in the heart. Evid Based Complement Alternat Med 340 185. PMID: 22011436.
Yoshimoto et al (2006) Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus. Proc Natl Acad Sci U S A 103 13866. PMID: 16954192.
Do you know of a great paper that uses Imetit dihydrobromide from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Imetit dihydrobromide, supplier, H3, H4, agonists, Receptors, Histamine, histaminergic, Tocris Bioscience, Histamine H3 Receptor Agonist products
Find multiple products by catalog number
One Day Symposium
March 1, 2017
Amsterdam, The Netherlands